Combining the strength of genomics, nanoparticle technology, and direct intraductal delivery for breast cancer treatment.
A large number of genes are altered in cancer cells. Often, reversal or inhibition of just one of these alterations leads to death of the cancer cells. Technological advances in multiple areas are necessary to potentiate clinical translation of these findings. In a recent article, Brock and colleagues reported that overexpressed HOXA1 is a critical event in tumor progression in a mouse mammary tumor model. They developed HOXA1-small interfering RNA nanoparticles and achieved effective therapeutic doses by delivering them intraductally through the nipple to the site of the tumor and at the same time circumvented the systemic immune response. This study strengthens the concept of targeting overexpressed genes by using small interfering RNA and bypassing systemic immunity through local intraductal delivery.
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650, Orleans Street, CRB1/143, Baltimore, MD, 21231, USA. wteo2@jhmi.edu.
Wei Wen
WW
Teo
Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650, Orleans Street, CRB1/143, Baltimore, MD, 21231, USA. saras@jhmi.edu.
Saraswati
S
Sukumar
D000818:Animals; D020868:Gene Silencing; D018398:Homeodomain Proteins / Q000235:genetics*; D008325:Mammary Neoplasms, Experimental / Q000473:pathology*; D053758:Nanoparticles; D034741:RNA, Small Interfering / Q000008:administration & dosage*; D014157:Transcription Factors / Q000235:genetics*
D018398:Homeodomain Proteins; D034741:RNA, Small Interfering; D014157:Transcription Factors